首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   21篇
  免费   1篇
妇产科学   1篇
基础医学   4篇
临床医学   4篇
内科学   3篇
特种医学   1篇
综合类   3篇
预防医学   1篇
药学   4篇
肿瘤学   1篇
  2022年   1篇
  2021年   1篇
  2020年   3篇
  2019年   1篇
  2014年   2篇
  2013年   1篇
  2012年   1篇
  2011年   2篇
  2008年   1篇
  2007年   2篇
  2005年   1篇
  2004年   1篇
  2000年   1篇
  1999年   1篇
  1998年   2篇
  1984年   1篇
排序方式: 共有22条查询结果,搜索用时 156 毫秒
1.
目的通过分析医科达Precise医用电子直线加速器运动系统原理及相关故障,探讨维修方法,为直线加速器维修提供借鉴意义。方法深入分析医科达Precise加速器运动系统原理,总结仪器特定角度、反方向运动伴抖动现象报i70 Gantry联锁错误、机架不能旋转无联锁报错以及6 MV能量模式报i517 Sctr Limit联锁错误的4例故障,分析可能的故障原因,进行一一排查。结果通过更换电位器、模拟输出板板A08-A、16脚接线、限位开关SW16将出现的4例故障快速有效地解决。结论充分掌握加速器工作原理,根据故障现象,可通过理论分析和实际测量快速排除故障,有效保证设备开机率和良好的运行状态。  相似文献   
2.

Background

Sophora flavescens Ait. is a traditional Chinese medicine with a long history in China. It is mainly used in the treatment of heat dysentery and similar ailments in the clinical. The objective of this paper was to isolate, purify and identify alkaloids from Sophora flavescens Ait. and to explore their inhibitory effects on C6 glioma cells.

Materials and Methods

Column chromatography, extraction and NMR spectroscopy were used to structurally identify the isolated compounds. MTT assay and flow cytometry were used to detect the inhibitory effect of matrine on C6 cells.

Results

Three compounds were isolated from Sophora flavescens Ait., namely matrine, oxymatrine and lupeol. Different concentrations of matrine solution all had inhibitory effects on growth of C6 cell lines, which showed apparent dose-effect relationship. Compared with the control group, proportion of G0/G1 phase cells increased in each matrine concentration group to a maximum of 79.8%; proportion of S phase cells reduced, and proportion of G2/M phase cells declined slightly to a minimum of 6.3%, suggesting that after the action of matrine proliferation of C6 cells was significantly inhibited and the cells were arrested in the G1 phase.

Conclusion

We concluded that Sophora flavescens Ait. has an inhibitory effect on C6 cell proliferation.  相似文献   
3.
Li  Jia  Xue  Zhixin  Wu  Zhenbiao  Bi  Liqi  Liu  Huaxiang  Wu  Lijun  Liu  Shengyun  Huang  Xiangyang  Wang  Yong  Zhang  Yan  Qi  Wufang  He  Lan  Dai  Lie  Sun  Lingyun  Li  Xiaomei  Shuai  Zongwen  Zhao  Yi  Wang  Yanyan  Xu  Jian  Zhang  Hao  Yu  Hao  Chen  Xiaoxiang  Bao  Chunde 《Clinical rheumatology》2022,41(10):3005-3016
Clinical Rheumatology - To assess the clinical equivalence of TQ-Z2301, a biosimilar of adalimumab, to the reference adalimumab in the treatment of Chinese patients with active ankylosing...  相似文献   
4.
目的了解该院2007~2009年泌尿生殖道解脲脲原体(Uu)感染状况及耐药性,为临床合理使用抗菌药物提供参考依据。方法临床正确采集标本后,采用培养药敏一体化的方法监测9种抗菌药物对Uu的耐药情况及用核酸扩增定量检测UuDNA的情况。结果 959例可疑病例培养中,男女感染率分别为20.2%、54.9%。其中Uu感染占39.6%(380/959),人型支原体(Mh)感染4例,Uu+Mh混合感染2例。380例Uu对原始霉素、交沙霉素、强力霉素的敏感率较高,分别为94.9%、93.9%和90.3%,对氧氟沙星、环丙沙星的敏感率较低,分别为12.5%和8.5%。785例Uu-DNA检测中,检出Uu401例,阳性率51.1%。结论 Uu的感染在病例中所占比例最高。原始霉素、交沙霉素、强力霉素敏感率高,对支原体感染有良好的治疗作用;氧氟沙星、环丙沙星敏感率低,不宜用于治疗泌尿生殖道支原体感染。  相似文献   
5.
淋巴瘤样肉芽肿与韦格内肉芽肿临床特点的比较   总被引:2,自引:0,他引:2  
戚务芳  蒋明  赵岩 《北京医学》2005,27(1):15-17
目的 总结淋巴瘤样肉芽肿病(lym phom atoid granulom atosis,LG)与韦格内肉芽肿( egener granulo Wm atosis,W G)的临床特点,从临床上加以鉴别。 方法 回顾性总结我院与北京协和医院 1989 年以来收治的 6 例 LG和20 例 W G 患者的临床资料,并进行比较。 结果 发热、咳嗽及呼吸困难在 LG 中较常见,流涕、鼻衄及关节痛以W G 为多,肺受累以 LG 为多,耳鼻喉、眼及肾病变在 W G 中明显增多,皮肤受损两者相似。W G 患者常有 c-ANCA 阳性及尿沉渣异常。 LG X 线胸片为双侧多发结节,边界不清,多无肺门、纵隔淋巴结肿大; G 则为双侧多发边界清晰W的结节, 易形成空洞, 肺门和纵隔淋巴结可肿大。LG 病理改变为血管中心性淋巴增生性病变, 浸润的细胞主要是小淋巴细胞和不同数量大的不典型淋巴细胞; 而在 W G 中可见坏死性血管炎及大量中性白细胞、浆细胞及少量嗜酸细胞浸润形成的肉芽肿, 部分有多核巨细胞。W G 经治疗后, 多数患者病情缓解; 则疗效不佳。 结论 LG 和 W G 在临 LG床表现、实验室检查、 影像及病理诸方面的差异有利于两者的鉴别诊断。  相似文献   
6.
GPR56 is an orphan G protein - coupled receptor, mutations of which have recently been associated with bilateral frontoparietal polymicrogyria, a rare neurologic disease that has implications in brain development. However, no phenotype beyond central nervous system has yet been described for the GPR56-null mutations despite abundant GPR56 expression in many non - central nervous system adult tissues. In the present study, we show that higher GPR56 expression is correlated with the cellular transformation phenotypes of several cancer tissues compared with their normal counterparts, implying a potential oncogenic function. RNA interference-mediated GPR56 silencing results in apoptosis induction and reduced anchorage-independent growth of cancer cells via increased anoikis, whereas cDNA overexpression resulted in increased foci formation in mouse fibroblast NIH3T3 cell line. When GPR56 silencing was induced in vivo in several xenograft tumor models, significant tumor responses (including regression) were observed, suggesting the potential of targeting GPR56 in the development of tumor therapies. The expression profiling of GPR56-silenced A2058 melanoma cell line revealed several genes whose expression was affected by GPR56 silencing, particularly those in the integrin-mediated signaling and cell adhesion pathways. The potential role of GPR56 in cancer cell adhesion was further confirmed by the observation that GPR56 silencing also reduced cell adhesion to the extracellular matrix, which is consistent with the observed increase in anoikis and reduction in anchorage-independent growth phenotypes. The oncogenic potential and apparent absence of physiologic defects in adult human tissues lacking GPR56, as well as the targetable nature of G protein - coupled receptor by small molecule or antibody, make GPR56 an attractive drug target for the development of cancer therapies.  相似文献   
7.
目的:了解该院血培养标本中检出病原菌的分布及耐药情况,为临床合理选用抗菌药物提供依据。方法对该院2011年1月至2012年6月的血培养结果进行回顾性分析。结果血培养标本培养3164份,阳性标本418份,占13.21%。革兰阳性菌176株,占阳性菌的42.11%,以金黄色葡萄球菌及凝固酶阴性葡萄球菌为主;革兰阴性菌235株,占阳性菌的56.22%,以大肠埃希菌及肺炎克雷伯菌为主;假丝酵母菌7株,占阳性菌的1.67%。送检标本最多的分别是新生儿科(627份)、血液科(367份)、呼吸科(272份)、儿科(207份)、神经内科(185份)、ICU(158份)。菌株分出率居前的分别肝胆外科(22.22%)、内分泌科(18.18%)、脊柱外科(16.36%)、ICU (15.96%)、神经外科(15.62%)、神经内科(15.13%)、肿瘤科(13.92%)、泌尿外科(12.23%)、烧伤儿外(12.15%)和骨外科(10.25%)。主要革兰阳性菌中,葡萄球菌对青霉素、红霉素、克林霉素、复方新诺明有很高的耐药性,凝固酶阴性葡萄球菌对喹喏酮类有较高的耐药性,尚未发现耐万古霉素和利奈唑胺的葡萄球菌。阴性杆菌中肠杆菌科细菌对亚胺培南、厄他培南、阿米卡星都有很强的敏感性;大肠埃希菌对青霉素、头孢类、氨曲南、喹喏酮类、复方新诺明、庆大霉素、妥布霉素都有较高的耐药性,均在40%以上,对氨苄西林、氨苄西林/舒巴坦的耐药率在90%左右,但对哌拉西林/他唑巴坦很敏感,耐药率小于5%;肺炎克雷伯菌的耐药性较低,只有氨苄西林、呋喃妥因的耐药率在90%以上,其他均在30%以下;阴沟肠杆菌对氨苄西林、氨苄西林/舒巴坦、第三代头孢、妥布霉素、头孢替坦、呋喃妥因的耐药性均较高,对第四代头孢、哌拉西林/他唑巴坦、喹喏酮类的耐药性较低。结论血培养病原菌种类复杂,以条件致病菌为主,耐药性较强,因此,临床应加强疑为败血症患者的血培养标本检测,尽早准确合理应用抗菌药物,提高治愈率。  相似文献   
8.
本文报告了用ELISA技术检测森脑病毒IgG抗体的实验条件和方法,并与HIT和CFT作了比较。抗原由感染鼠脑经鱼精蛋白处理-聚乙二醇浓缩及蔗糖密度梯度离心纯化制备。共检测了109份血清,结果发现ELISA与HIT的检出符合率为93.6%,与CFT的检出符合率为86.2%;ELISA与HIT和CFT的相应检出滴度相关非常显著(rHIT=0.9550,rCFT=0.8912,P<0.001),且比HIT和CFT分别敏感10~80倍及50~200倍,未发现与乙脑免疫血清存在交叉反应。ELISA技术特异性和重复性均好,所需标本量少且不需预先处理,可代替常规方法用于森脑的临床诊断、血清流行病学调查等研究。  相似文献   
9.
BackgroundFew studies have focused on the ability of progranulin to predict postoperative disease activity in rheumatoid arthritis (RA) patients who have undergone surgery. This study evaluated serum progranulin levels in active RA patients and analyzed its relationship with postoperative disease activity.MethodsOne hundred thirty-two patients with active RA and 72 healthy subjects were included in this study. Serum progranulin was measured, and clinical data were collected. The postoperative 1-year Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) scores was evaluated as an indicator of disease activity. The predictive value of progranulin in postoperative 1-year disease activity in RA patients was also analyzed.ResultsSerum progranulin was significantly associated with the postoperative 1-year RA disease activity. The mean serum progranulin level in patients with a high disease activity was significantly higher than that of RA patients with low-to-moderate disease activity (54.2 ± 10.6 ng/mL vs. 46.7 ± 8.8 ng/mL). Serum progranulin was also evaluated as an independent predictive factor for postoperative 1-year RA disease activity in multivariate analysis (odds ratio [OR], 2.21; 95% confidence interval [CI], 1.02–8.85).ConclusionsSerum progranulin levels may be a promising indicator of postoperative disease activity in RA patients who underwent orthopedic surgery.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号